Written answers
Tuesday, 19 February 2019
Department of Health
Medicinal Products Availability
Willie O'Dea (Limerick City, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
328. To ask the Minister for Health the status of the approval of the drug Spinraza for availability under the general medical services system; and if he will make a statement on the matter. [7727/19]
Seán Haughey (Dublin Bay North, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
383. To ask the Minister for Health if the drug known as Spinraza will be made available to persons with spinal muscular atrophy; and if he will make a statement on the matter. [8009/19]
Peadar Tóibín (Meath West, Sinn Fein)
Link to this: Individually | In context | Oireachtas source
388. To ask the Minister for Health when Spinraza treatment will be rolled out to persons with spinal muscular atrophy; and if he will make a statement on the matter. [8028/19]
Seán Sherlock (Cork East, Labour)
Link to this: Individually | In context | Oireachtas source
395. To ask the Minister for Health when a drug (details supplied) will be made available. [8119/19]
Denis Naughten (Roscommon-Galway, Independent)
Link to this: Individually | In context | Oireachtas source
415. To ask the Minister for Health when a decision will be made on making Spinraza available to children with spinal muscular atrophy; and if he will make a statement on the matter. [8205/19]
Robert Troy (Longford-Westmeath, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
434. To ask the Minister for Health the status of the application for reimbursement for Nusinersen for the treatment of spinal muscular atrophy; if he has engaged with the HSE in an effort to advance this process; and if he will make a statement on the matter. [8324/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 328, 383, 388, 395, 415 and 434 together.
The Health Service Executive has statutory responsibility for decisions on pricing and reimbursement of medicines, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
The Act specifies the criteria to be applied in the making of reimbursement decisions which include the clinical and cost effectiveness of the product, the opportunity cost and the impact on resources that are available to the HSE.
I am advised by the HSE that the application for the reimbursement of Nusinersen (Spinraza) was considered by HSE Leadership at a meeting on 12 February 2019 and that the HSE is in the process of communicating its decision to the relevant company.
No comments